Αποτελέσματα αναζήτησης - Joshua F. Zeidner

  • Εμφανίζονται 1 - 16 Αποτελέσματα από 16
Περιορισμός αποτελεσμάτων
  1. 1
    Conjugation of haematopoietic stem cells and platelets decorated with anti-PD-1 antibodies augments anti-leukaemia efficacy

    Conjugation of haematopoietic stem cells and platelets decorated with anti-PD-1 antibodies augments anti-leukaemia efficacy από Quanyin Hu, Wujin Sun, Jinqiang Wang, Huitong Ruan, Xudong Zhang, Yanqi Ye, Song Shen, Chao Wang, Weiyue Lu, Ke Cheng, Gianpietro Dotti, Joshua F. Zeidner, Jun Wang, Zhen Gu

    Έκδοση 2018
    Λήψη πλήρους κειμένου
    Artigo
    Προσθήκη στα αγαπημένα
    Αποθηκεύτηκε σε:
  2. 2
    Signatures of CD8+ T cell dysfunction in AML patients and their reversibility with response to chemotherapy

    Signatures of CD8+ T cell dysfunction in AML patients and their reversibility with response to chemotherapy από Hanna A. Knaus, Sofia Berglund, Hubert Hackl, Amanda L. Blackford, Joshua F. Zeidner, Raul Montiel‐Esparza, Rupkatha Mukhopadhyay, Katrina Vanura, Bruce R. Blazar, Judith E. Karp, Leo Luznik, Ivana Gojo

    Έκδοση 2018
    Λήψη πλήρους κειμένου Λήψη πλήρους κειμένου
    Artigo
    Προσθήκη στα αγαπημένα
    Αποθηκεύτηκε σε:
  3. 3
    A phase II trial of sequential ribonucleotide reductase inhibition in aggressive myeloproliferative neoplasms

    A phase II trial of sequential ribonucleotide reductase inhibition in aggressive myeloproliferative neoplasms από Joshua F. Zeidner, J. E. Karp, Amanda L. Blackford, B. D. Smith, Ivana Gojo, Steven D. Gore, Mark J. Levis, Hetty E. Carraway, Judith M. Greer, S. Percy Ivy, Keith W. Pratz, Michael A. McDevitt

    Έκδοση 2013
    Λήψη πλήρους κειμένου Λήψη πλήρους κειμένου
    Artigo
    Προσθήκη στα αγαπημένα
    Αποθηκεύτηκε σε:
  4. 4
    Randomized phase 2 trial of pevonedistat plus azacitidine versus azacitidine for higher-risk MDS/CMML or low-blast AML

    Randomized phase 2 trial of pevonedistat plus azacitidine versus azacitidine for higher-risk MDS/CMML or low-blast AML από Mikkael A. Sekeres, Justin M. Watts, Atanas Radinoff, Montserrat Arnán Sangerman, Marco Cerrano, Patricia Font, Joshua F. Zeidner, María Díez‐Campelo, Carlos Graux, Jane L. Liesveld, Dominik Selleslag, Nikolay Tzvetkov, Robert J. Fram, Dan Zhao, Jill A. Bell, Sharon Friedlander, Douglas V. Faller, Lionel Adès

    Έκδοση 2021
    Λήψη πλήρους κειμένου Λήψη πλήρους κειμένου
    Carta
    Προσθήκη στα αγαπημένα
    Αποθηκεύτηκε σε:
  5. 5
    Pevonedistat, a first-in-class NEDD8-activating enzyme inhibitor, combined with azacitidine in patients with AML

    Pevonedistat, a first-in-class NEDD8-activating enzyme inhibitor, combined with azacitidine in patients with AML από Ronan Swords, Steven Coutré, Michael B. Maris, Joshua F. Zeidner, James M. Foran, José C. Cruz, Harry P. Erba, Jesús G. Berdeja, Wayne Tam, Saran Vardhanabhuti, Iwona Pawlikowska-Dobler, Hélène M. Faessel, Ajeeta B. Dash, Farhad Sedarati, Bruce J. Dezube, Douglas V. Faller, Michael R. Savona

    Έκδοση 2018
    Λήψη πλήρους κειμένου Λήψη πλήρους κειμένου
    Artigo
    Προσθήκη στα αγαπημένα
    Αποθηκεύτηκε σε:
  6. 6
    Immune dysfunction signatures predict outcomes and define checkpoint blockade–unresponsive microenvironments in acute myeloid leukemia

    Immune dysfunction signatures predict outcomes and define checkpoint blockade–unresponsive microenvironments in acute myeloid leukemia από Sergio Rutella, Jayakumar Vadakekolathu, Francesco Mazziotta, Stephen Reeder, Tung On Yau, Rupkatha Mukhopadhyay, Benjamin Dickins, Heidi Altmann, Michael Krämer, Hanna A. Knaus, Bruce R. Blazar, Vedran Radojčić, Joshua F. Zeidner, Andrea Arruda, Bofei Wang, Hussein A. Abbas, Mark D. Minden, Sarah K. Tasian, Martin Bornhäuser, Ivana Gojo, Leo Luznik

    Έκδοση 2022
    Λήψη πλήρους κειμένου Λήψη πλήρους κειμένου
    Artigo
    Προσθήκη στα αγαπημένα
    Αποθηκεύτηκε σε:
  7. 7
    Randomized multicenter phase II study of flavopiridol (alvocidib), cytarabine, and mitoxantrone (FLAM) versus cytarabine/daunorubicin (7+3) in newly diagnosed acute myeloid leukemia

    Randomized multicenter phase II study of flavopiridol (alvocidib), cytarabine, and mitoxantrone (FLAM) versus cytarabine/daunorubicin (7+3) in newly diagnosed acute myeloid leukemi... από Joshua F. Zeidner, M. C. Foster, Amanda L. Blackford, M. R. Litzow, L. E. Morris, Stephen A. Strickland, J. E. Lancet, Prithviraj Bose, M. Y. Levy, Raoul Tibes, Ivana Gojo, C. D. Gocke, G. L. Rosner, R. F. Little, J. J. Wright, L. A. Doyle, B. D. Smith, J. E. Karp

    Έκδοση 2015
    Λήψη πλήρους κειμένου Λήψη πλήρους κειμένου
    Artigo
    Προσθήκη στα αγαπημένα
    Αποθηκεύτηκε σε:
  8. 8
    Multi-Center Phase 2 Study of Pembroluzimab (Pembro) and Azacitidine (AZA) in Patients with Relapsed/Refractory Acute Myeloid Leukemia (AML) and in Newly Diagnosed (≥65 Years) AML Patients

    Multi-Center Phase 2 Study of Pembroluzimab (Pembro) and Azacitidine (AZA) in Patients with Relapsed/Refractory Acute Myeloid Leukemia (AML) and in Newly Diagnosed (≥65 Years) AML... από Ivana Gojo, Robert K. Stuart, Jonathan Webster, Amanda L. Blackford, Juan Carlos Varela, Jillian Morrow, Amy E. DeZern, Matthew C. Foster, Mark J. Levis, Catherine C. Coombs, Gabrielle T. Prince, B. Douglas Smith, Hendrik W. van Deventer, Katarzyna Jamieson, Ravi Varadhan, Benjamin G. Vincent, Jonathan S. Serody, Leo Luznik, Joshua F. Zeidner

    Έκδοση 2019
    Λήψη πλήρους κειμένου
    Artigo
    Προσθήκη στα αγαπημένα
    Αποθηκεύτηκε σε:
  9. 9
    Tolerability and Efficacy of the Anticluster of Differentiation 47 Antibody Magrolimab Combined With Azacitidine in Patients With Previously Untreated AML: Phase Ib Results

    Tolerability and Efficacy of the Anticluster of Differentiation 47 Antibody Magrolimab Combined With Azacitidine in Patients With Previously Untreated AML: Phase Ib Results από Naval Daver, Paresh Vyas, Suman Kambhampati, Monzr M. Al Malki, Richard A. Larson, Adam S. Asch, Gabriel N. Mannis, Wanxing Chai‐Ho, Tiffany Tanaka, Terrence Bradley, Deepa Jeyakumar, Eunice S. Wang, Kendra Sweet, Hagop M. Kantarjian, Guillermo Garcia‐Manero, Rami S. Komrokji, Guan Xing, Giridharan Ramsingh, Camille Renard, Joshua F. Zeidner, David A. Sallman

    Έκδοση 2023
    Λήψη πλήρους κειμένου Λήψη πλήρους κειμένου
    Artigo
    Προσθήκη στα αγαπημένα
    Αποθηκεύτηκε σε:
  10. 10
    Magrolimab plus azacitidine vs physician's choice for untreated TP53-mutated acute myeloid leukemia: the ENHANCE-2 study

    Magrolimab plus azacitidine vs physician's choice for untreated TP53-mutated acute myeloid leukemia: the ENHANCE-2 study από Joshua F. Zeidner, David A. Sallman, Christian Récher, Naval Daver, Anskar YH Leung, Devendra Hiwase, Kai Rejeski, Thomas Pabst, Pau Montesinos, Richard A. Larson, Lindsay Wilde, Anoop K. Enjeti, Ichiro Kawashima, Cristina Papayannidis, Jenny O’Nions, Lisa D. Johnson, Mei Dong, Julie Y. Huang, Taravat Bagheri, Gal Hacohen-Kleiman, Calvin Lee, Paresh Vyas

    Έκδοση 2025
    Λήψη πλήρους κειμένου
    Artigo
    Προσθήκη στα αγαπημένα
    Αποθηκεύτηκε σε:
  11. 11
    A Multi-center Phase I Trial of Ipilimumab in Patients with Myelodysplastic Syndromes following Hypomethylating Agent Failure

    A Multi-center Phase I Trial of Ipilimumab in Patients with Myelodysplastic Syndromes following Hypomethylating Agent Failure από Amer M. Zeidan, Hanna A. Knaus, Tara M. Robinson, Andrea Towlerton, Edus H. Warren, Joshua F. Zeidner, Amanda L. Blackford, Amy S. Duffield, David A. Rizzieri, Mark G. Frattini, Yair Levy, Mark A. Schroeder, Anna Ferguson, Katherine E. Sheldon, Amy E. DeZern, Ivana Gojo, Steven D. Gore, Howard Streicher, Leo Luznik, B. Douglas Smith

    Έκδοση 2018
    Λήψη πλήρους κειμένου
    Artigo
    Προσθήκη στα αγαπημένα
    Αποθηκεύτηκε σε:
  12. 12
    Phase II Trial of Pembrolizumab after High-Dose Cytarabine in Relapsed/Refractory Acute Myeloid Leukemia

    Phase II Trial of Pembrolizumab after High-Dose Cytarabine in Relapsed/Refractory Acute Myeloid Leukemia από Joshua F. Zeidner, Benjamin G. Vincent, Anastasia Ivanova, Dominic T. Moore, Karen P. McKinnon, Alec Wilkinson, Rupkatha Mukhopadhyay, Francesco Mazziotta, Hanna A. Knaus, Matthew C. Foster, Catherine C. Coombs, Katarzyna Jamieson, Hendrik Van Deventer, Jonathan Webster, Gabrielle T. Prince, Amy E. DeZern, B. Douglas Smith, Mark J. Levis, Nathan D. Montgomery, Leo Luznik, Jonathan S. Serody, Ivana Gojo

    Έκδοση 2021
    Λήψη πλήρους κειμένου Λήψη πλήρους κειμένου
    Artigo
    Προσθήκη στα αγαπημένα
    Αποθηκεύτηκε σε:
  13. 13
    Magrolimab in Combination With Azacitidine in Patients With Higher-Risk Myelodysplastic Syndromes: Final Results of a Phase Ib Study

    Magrolimab in Combination With Azacitidine in Patients With Higher-Risk Myelodysplastic Syndromes: Final Results of a Phase Ib Study από David A. Sallman, Monzr M. Al Malki, Adam S. Asch, Eunice S. Wang, Joseph G. Jurcic, Terrence Bradley, Ian W. Flinn, Daniel A. Pollyea, Suman Kambhampati, Tiffany Tanaka, Joshua F. Zeidner, Guillermo Garcia‐Manero, Deepa Jeyakumar, Rami S. Komrokji, Jeffrey E. Lancet, Hagop M. Kantarjian, Lin Gu, Yajia Zhang, Anderson Tan, Mark P. Chao, Carol O’Hear, Giridharan Ramsingh, Indu Lal, Paresh Vyas, Naval Daver

    Έκδοση 2023
    Λήψη πλήρους κειμένου Λήψη πλήρους κειμένου
    Artigo
    Προσθήκη στα αγαπημένα
    Αποθηκεύτηκε σε:
  14. 14
    Targeting PRMT9-mediated arginine methylation suppresses cancer stem cell maintenance and elicits cGAS-mediated anticancer immunity

    Targeting PRMT9-mediated arginine methylation suppresses cancer stem cell maintenance and elicits cGAS-mediated anticancer immunity από Haojie Dong, Xin He, Lei Zhang, Wei Chen, Yi‐Chun Lin, Songbai Liu, Huafeng Wang, Le Xuan Truong Nguyen, Min Li, Yinghui Zhu, Dandan Zhao, Lucy Ghoda, Jonathan S. Serody, Benjamin G. Vincent, Leo Luznik, Ivana Gojo, Joshua F. Zeidner, Rui Su, Jianjun Chen, Ritin Sharma, Patrick Pirrotte, Xiwei Wu, Weidong Hu, Weidong Han, Binghui Shen, Ya‐Huei Kuo, Jie Jin, Amandeep Salhotra, Jeffrey Wang, Guido Marcucci, Yun Luo, Ling Li

    Έκδοση 2024
    Λήψη πλήρους κειμένου Λήψη πλήρους κειμένου
    Artigo
    Προσθήκη στα αγαπημένα
    Αποθηκεύτηκε σε:
  15. 15
    Molecular characterization of newly diagnosed acute myeloid leukemia patients aged 60 years or older: a report from the Beat AML clinical trial

    Molecular characterization of newly diagnosed acute myeloid leukemia patients aged 60 years or older: a report from the Beat AML clinical trial από Fieke W. Hoff, Ying Huang, Rina Li Welkie, Ronan Swords, Elie Traer, Eytan M. Stein, Tara L. Lin, Prapti A. Patel, Robert H. Collins, Maria R. Baer, Vu H. Duong, William Blum, Martha Arellano, Wendy Stock, Olatoyosi Odenike, Robert L. Redner, Tibor Kovacsovics, Michael W. Deininger, Joshua F. Zeidner, Rebecca L. Olin, Catherine C. Smith, James M. Foran, Gary J. Schiller, Emily Curran, Kristin L Koenig, Nyla A. Heerema, Timothy Chen, Molly Martycz, Mona Stefanos, Sonja Marcus, Leonard Rosenberg, Brian J. Druker, Ross L. Levine, Amy Burd, Ashley O. Yocum, Uma Borate, Alice S. Mims, John C. Byrd, Yazan F. Madanat

    Έκδοση 2025
    Λήψη πλήρους κειμένου
    Carta
    Προσθήκη στα αγαπημένα
    Αποθηκεύτηκε σε:
  16. 16
    Special considerations in the management of adult patients with acute leukaemias and myeloid neoplasms in the COVID-19 era: recommendations from a panel of international experts

    Special considerations in the management of adult patients with acute leukaemias and myeloid neoplasms in the COVID-19 era: recommendations from a panel of international experts από Amer M. Zeidan, Prajwal Boddu, Mrinal M. Patnaik, Jan Philipp Bewersdorf, Maximilian Stahl, Raajit K. Rampal, Rory M. Shallis, David P. Steensma, Michael R. Savona, Mikkael A. Sekeres, Gail J. Roboz, Daniel J. DeAngelo, Andre C. Schuh, Eric Padron, Joshua F. Zeidner, Roland B. Walter, Francesco Onida, Amir T. Fathi, Amy E. DeZern, Gabriela S. Hobbs, Eytan M. Stein, Paresh Vyas, Andrew H. Wei, David Bowen, Pau Montesinos, Elizabeth A. Griffiths, Amit Verma, Alla Keyzner, Michal Bar‐Natan, Shyamala C. Navada, Marina Kremyanskaya, Aaron D. Goldberg, Aref Al‐Kali, Mark Heaney, Aziz Nazha, Huda Salman, Selina M. Luger, Keith W. Pratz, Helmut König, Rami S. Komrokji, Michael W. Deininger, Blanca Xicoy Cirici, Vijaya Raj Bhatt, Lewis R. Silverman, Harry P. Erba, Pierre Fenaux, Uwe Platzbecker, Valeria Santini, Eunice S. Wang, Martin S. Tallman, Richard M. Stone, John Mascarenhas

    Έκδοση 2020
    Λήψη πλήρους κειμένου Λήψη πλήρους κειμένου
    Revisão
    Προσθήκη στα αγαπημένα
    Αποθηκεύτηκε σε:

Εργαλεία αναζήτησης: